Based on the Acumen Pharmaceuticals Inc stock forecast from 4 analysts, the average analyst target price for Acumen Pharmaceuticals Inc is USD 11.50 over the next 12 months. Acumen Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Acumen Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Acumen Pharmaceuticals Inc’s stock price was USD 2.26. Acumen Pharmaceuticals Inc’s stock price has changed by -4.64% over the past week, -22.07% over the past month and -3.42% over the last year.
No recent analyst target price found for Acumen Pharmaceuticals Inc
No recent average analyst rating found for Acumen Pharmaceuticals Inc
Company Overview Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. Address: 427 Park Street, Charlottesville, VA, United States, 22902 Read Less
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gam...Read More
Frequently Asked Questions About Acumen Pharmaceuticals Inc (ABOS) Stock
Based on ratings from 4 analysts Acumen Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on ABOS's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ABOS is USD 11.50 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 6.
ABOS stock's Price/Earning ratio is 3.26.
Our analysis grades ABOS stock's Price / Earning ratio at F. This means that ABOS stock's Price/Earning ratio is above 43.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ABOS may be fairly valued for its sector
The last closing price of ABOS's stock was USD 2.26.
The most recent market capitalization for ABOS is USD 0.13B.
Based on targets from 4 analysts, the average taret price for ABOS is projected at USD 11.50 over the next 12 months.
This means that ABOS's stock price may go up by +408.85% over the next 12 months.
We can't find any ETFs which contains Acumen Pharmaceuticals Inc's stock.
As per our most recent records Acumen Pharmaceuticals Inc has 51 Employees.
Acumen Pharmaceuticals Inc's registered address is 427 Park Street, Charlottesville, VA, United States, 22902.
You can get more information about it from Acumen Pharmaceuticals Inc's website at https://acumenpharm.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Acumen Pharmaceuticals Inc (ABOS) Stock
Based on ratings from 4 analysts Acumen Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on ABOS's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for ABOS is USD 11.50 over the next 12 months. The maximum analyst target price is USD 15 while the minimum anlayst target price is USD 6.
ABOS stock's Price/Earning ratio is 3.26.
Our analysis grades ABOS stock's Price / Earning ratio at F. This means that ABOS stock's Price/Earning ratio is above 43.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ABOS may be fairly valued for its sector
The last closing price of ABOS's stock was USD 2.26.
The most recent market capitalization for ABOS is USD 0.13B.
Based on targets from 4 analysts, the average taret price for ABOS is projected at USD 11.50 over the next 12 months.
This means that ABOS's stock price may go up by +408.85% over the next 12 months.
We can't find any ETFs which contains Acumen Pharmaceuticals Inc's stock.
As per our most recent records Acumen Pharmaceuticals Inc has 51 Employees.
Acumen Pharmaceuticals Inc's registered address is 427 Park Street, Charlottesville, VA, United States, 22902.
You can get more information about it from Acumen Pharmaceuticals Inc's website at https://acumenpharm.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ABOS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
